Joel Greenblatt’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$251K Sell
803
-2,807
-78% -$830K ﹤0.01% 1749
2026
Q2
$1.14M Sell
3,610
-562
-13% -$132K ﹤0.01% 1322
2026
Q1
$833K Sell
4,172
-5,174
-55% -$1.02M ﹤0.01% 1363
2025
Q4
$1.77M Sell
9,346
-129
-1% -$24.8K 0.01% 1074
2025
Q3
$1.68M Buy
+9,475
New +$1.41M 0.01% 1049
2025
Q2
– Sell
-6,912
Closed -$727K – 1710
2025
Q1
$727K Buy
+6,912
New +$782K 0.01% 1101
2024
Q1
– Sell
-4,183
Closed -$299K – 1424
2023
Q4
$299K Sell
4,183
-3,300
-44% -$195K 0.01% 1139
2023
Q3
$448K Sell
7,483
-1,799
-19% -$118K 0.01% 993
2023
Q2
$669K Buy
9,282
+5,037
+119% +$378K 0.01% 887
2023
Q1
$312K Buy
+4,245
New +$302K 0.01% 1115
2022
Q4
– Sell
-4,543
Closed -$391K – 1268
2022
Q3
$391K Buy
4,543
+1,400
+45% +$132K 0.01% 905
2022
Q2
$280K Sell
3,143
-1,437
-31% -$131K 0.01% 962
2022
Q1
$515K Buy
4,580
+1,122
+32% +$130K 0.02% 794
2021
Q4
$534K Buy
3,458
+1,051
+44% +$156K 0.02% 753
2021
Q3
$335K Sell
2,407
-155
-6% -$19.2K 0.01% 780
2021
Q2
$336K Buy
2,562
+526
+26% +$70.1K 0.01% 803
2021
Q1
$310K Sell
2,036
-1,679
-45% -$254K 0.01% 831
2020
Q4
$369K Buy
+3,715
New +$340K 0.01% 784
2020
Q1
– Sell
-2,468
Closed -$257K – 1148
2019
Q4
$257K Buy
2,468
+343
+16% +$36.7K ﹤0.01% 982
2019
Q3
$212K Sell
2,125
-62,546
-97% -$6.29M ﹤0.01% 998
2019
Q2
$7.38M Buy
64,671
+39,236
+154% +$4.63M 0.12% 243
2019
Q1
$3.2M Buy
25,435
+8,878
+54% +$1.08M 0.05% 416
2018
Q4
$2.25M Sell
16,557
-11,254
-40% -$1.92M 0.03% 467
2018
Q3
$7.63M Buy
27,811
+13,820
+99% +$3.34M 0.11% 267
2018
Q2
$2.9M Sell
13,991
-2,319
-14% -$415K 0.04% 425
2018
Q1
$2.69M Sell
16,310
-35,790
-69% -$5.67M 0.04% 452
2017
Q4
$7.13M Buy
+52,100
New +$7.24M 0.1% 293
2017
Q2
– Sell
-117,749
Closed -$12.5M – 1032
2017
Q1
$12.5M Buy
117,749
+83,784
+247% +$8.84M 0.16% 217
2016
Q4
$3.45M Sell
33,965
-4,266
-11% -$432K 0.04% 437
2016
Q3
$3.9M Sell
38,231
-33,639
-47% -$3.96M 0.05% 397
2016
Q2
$8.57M Buy
71,870
+50,048
+229% +$5.95M 0.1% 307
2016
Q1
$2.34M Buy
+21,822
New +$2.13M 0.03% 559
2015
Q1
– Sell
-3,766
Closed -$200K – 970
2014
Q4
$200K Sell
3,766
-548,287
-99% -$28.6M ﹤0.01% 914
2014
Q3
$25.9M Buy
552,053
+496,561
+895% +$26.4M 0.26% 143
2014
Q2
$3.46M Buy
+55,492
New +$3.61M 0.04% 450
2014
Q1
– Sell
-13,803
Closed -$726K – 1047
2013
Q4
$726K Buy
13,803
+7,667
+125% +$400K 0.02% 688
2013
Q3
$266K Buy
+6,136
New +$277K 0.01% 811

Other funds holding LGND

Joel Greenblatt's LGND Position: Q3 2026 in Review

Joel Greenblatt reduced its Ligand Pharmaceuticals (LGND) stake by 78% in Q3 2026, selling an estimated $830K and leaving 803 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Joel Greenblatt first reported a position in LGND in Q3 2013 and has held it in 37 quarters since. The position peaked at $25.9M in Q3 2014. 433 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • Joel Greenblatt held 803 shares of Ligand Pharmaceuticals worth $251K as of Q3 2026.
  • Joel Greenblatt sold 2,807 Ligand Pharmaceuticals shares in Q3 2026, an estimated $830K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q3 2026, its #1749 holding.
  • Joel Greenblatt first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 37 quarters since.
  • Joel Greenblatt's Ligand Pharmaceuticals position peaked at $25.9M in Q3 2014.
  • 433 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.